Video

It's an Exciting Time for Myelodysplastic Syndrome

Learning more about MDS will lead to better diagnostics and more personalized treatments.

It’s an exciting time in the field of myelodysplastic syndrome (MDS), explained Amy DeZern, M.D., associate professor of Oncology and Medicine at the Johns Hopkins University School of Medicine.

Researchers and practitioners alike are learning more about the biology of the disease, as well as the molecular mutations that come along with it. This is helping to differentiate different subtypes of MDS — it is not a heterogenous disease – which will lead to better diagnostic and prognostic accuracy, as well as paving the way for the use of targeted therapy in this space.

Related Videos
Image of Dr. Goy.
Dr. Tycel Phillips is an Associate Professor in the Division of Lymphoma, Department of Hematology and Hematopoietic Cell Transplantation, at City of Hope in Duarte, California.
Image of Dr. Salani.
Dr. Debu Tripathy is a professor and chairman of the Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, in Houston, and the editor-in-chief of CURE®.
Dr. Suneel Kamath is an assistant professor of medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, in Ohio.
Image of Dr. Fakih.
Dr. Catherine Wu is chief of the Division of Stem Cell Transplantation and Cellular Therapies at Dana-Farber Cancer Institute, and institute member at the Broad Institute of MIT and Harvard, in Boston, Massachusetts.
Dr. John Oertle discusses the key benefits to come from patients with cancer connecting with support networks, advocacy groups and resources.
Dr. Gabriel A. Brooks discussed the recent FDA product labeling update for Xeloda and 5-FU.
Dr. Alan Tan is the GU Oncology Lead at the Vanderbilt-Ingram Cancer Center in Nashville, Tennessee, as well as an associate professor in the Division of Hematology/Oncology at Vanderbilt University Medical Center and GU Executive Officer with the Alliance for Clinical Trials in Oncology.